Sign In
Buy INMB
$2.09
+0.180 (+9.42%)
At Close: Aug 07, 2026
INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
08:58pm, Saturday, 11'th May 2024
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer and Co-Founder Dr
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
04:05pm, Thursday, 09'th May 2024
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
08:00am, Tuesday, 07'th May 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the p
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
09:00am, Thursday, 25'th Apr 2024
Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the p
Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pa
Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the p
INmune Bio: An Opportunity In The Freefall (Rating Upgrade)
04:27am, Monday, 22'nd Apr 2024
INmune Bio is focused on developing drugs for neurology and cancer medicine. The company's most advanced product candidate is XPro 1595, which is being developed for Alzheimer's disease. INMB's financ
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer
INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
08:18pm, Thursday, 28'th Mar 2024
INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
04:01pm, Thursday, 28'th Mar 2024
BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
04:01pm, Tuesday, 26'th Mar 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage im
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
08:00am, Wednesday, 13'th Mar 2024
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy Recognizing Exceptional Contributions and Achievements in the Field
INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™
08:00am, Tuesday, 05'th Mar 2024
Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro™ therapy.
